熱門資訊> 正文

AVROBIO GAAP EPS of -$0.84 beats by $0.55

2025-03-21 04:45

AVROBIO(AVRO) 0
Tectonic Therapeutic Inc(TECX) 0

AVROBIO press release (NASDAQ:TECX): Q4 GAAP EPS of -$0.84 beats by $0.55.
As of December 31, 2024, cash and cash equivalents were $141.2 million, compared to $159.1 million as of September 30, 2024. Tectonic anticipates that, based on current operating assumptions, its current cash and cash equivalents will provide a cash runway into Q4’28, including through key Phase 1b and Phase 2 readouts for TX45, and the progression of the HHT program into clinical development.

More on AVROBIO

Tectonic: Expansion Of TX45 Candidate Possible After Positive Interim Data
Tectonic Therapeutic: Stock Spikes On Heart Failure Data -- Why I See Further Upside
Tectonic Therapeutic: Protein Engineering Platform For GPCRs
Tectonic announces ~$185M capital raise
Tectonic jumps on positive data from early-stage trial for lead asset

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。